Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Maria Victoria Borrás Pérez, Berit Kriström, Tomasz Romer, Mieczyslaw Walczak, Nadja Höbel & Markus Zabransky. (2017) Ten years of clinical experience with biosimilar human growth hormone: a review of safety data. Drug Design, Development and Therapy 11, pages 1497-1503.
Read now
Read now
Holger Schmid & Wolfgang Jelkmann. (2016) Investigational therapies for renal disease-induced anemia. Expert Opinion on Investigational Drugs 25:8, pages 901-916.
Read now
Read now
Holger Schmid. (2014) Cost-effectiveness of continuous erythropoietin receptor activator in anemia. ClinicoEconomics and Outcomes Research 6, pages 319-330.
Read now
Read now
Articles from other publishers (21)
Charles L. Bennett, Sumimasa Nagai, Andrew C. Bennett, Shamia Hoque, Chadi Nabhan, Martin W. Schoen, William J. Hrushesky, Stefano Luminari, Paul Ray, Paul R. Yarnold, Bart Witherspoon, Josh Riente, Laura Bobolts, John Brusk, Rebecca Tombleson, Kevin Knopf, Marc Fishman, Y. Tony Yang, Kenneth R. Carson, Benjamin Djulbegovic, John Restaino, James O. Armitage & Oliver A. Sartor. (2021) The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. The Oncologist 26:8, pages e1418-e1426.
Crossref
Crossref
N. Jung, W.-J. Mayet, P.R. Mertens, J. Meyer (federführend)O.-A. Müller, M. Pfeifer, P. Schellinger, N. Weiss & C.-M. Wendtner. 2020. Rationelle Diagnostik und Therapie in der Inneren Medizin. Rationelle Diagnostik und Therapie in der Inneren Medizin
B-1
B30-3
.
Yanyan Huo, Jinjiao He & Feng Li. (2019) Sialic Acids Content Analysis of the Innovator and Biosimilar Darbepoetin Alfa by Fluorometric HPLC Assay. Current Pharmaceutical Analysis 15:4, pages 333-337.
Crossref
Crossref
Dalvir Kular & Iain C. Macdougall. (2018) HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics. Pediatric Nephrology 34:3, pages 365-378.
Crossref
Crossref
Olivier Salamin, Tiia Kuuranne, Martial Saugy & Nicolas Leuenberger. (2018) Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects. Molecular and Cellular Endocrinology 464, pages 75-87.
Crossref
Crossref
Roy Jefferis. (2017) Biologics: structural heterogeneity and immunogenicity. British Journal of Hospital Medicine 78:8, pages 443-447.
Crossref
Crossref
Johanna Mielke, Bernd Jilma, Franz Koenig & Byron Jones. (2016) Clinical trials for authorized biosimilars in the European Union: a systematic review. British Journal of Clinical Pharmacology 82:6, pages 1444-1457.
Crossref
Crossref
Carlo Genova, Erika Rijavec & Francesco Grossi. (2016) Hematopoietic growth factors in lung cancer. Current Opinion in Oncology 28:2, pages 135-144.
Crossref
Crossref
Liem Andhyk Halim, Vera Brinks, Wim Jiskoot, Stefan Romeijn, Rob Haselberg, Chris Burns, Meenu Wadhwa & Huub Schellekens. (2016) Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products. Journal of Pharmaceutical Sciences 105:2, pages 542-550.
Crossref
Crossref
Roy Jefferis. (2016) Posttranslational Modifications and the Immunogenicity of Biotherapeutics. Journal of Immunology Research 2016, pages 1-15.
Crossref
Crossref
David J. Handelsman. 2016. Endocrinology: Adult and Pediatric. Endocrinology: Adult and Pediatric
441
454.e4
.
Sarfaraz Niazi. 2015. Biosimilars and Interchangeable Biologics. Biosimilars and Interchangeable Biologics
1
22
.
Mario Thevis & Wilhelm Schänzer. (2014) Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. Journal of Pharmaceutical and Biomedical Analysis 101, pages 66-83.
Crossref
Crossref
Bradley A. Warady & Douglas M. Silverstein. (2013) Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatric Nephrology 29:9, pages 1493-1505.
Crossref
Crossref
Bradley A. Warady, Alicia M. Neu & Franz Schaefer. (2014) Optimal Care of the Infant, Child, and Adolescent on Dialysis: 2014 Update. American Journal of Kidney Diseases 64:1, pages 128-142.
Crossref
Crossref
Salvatore Del Prete, Saverio Cinieri, Vito Lorusso, Luigi Maiorino, Carmine Pizza, Agata Pisano, Vincenzo Montesarchio, Luigi Leo, Clementina Savastano, Giuseppe Pistolese, Maddalena Bianco, Roberto Mabilia, Riccardo Tonachella, Antonio Febbraro, Luigi Manzione, Salvatore Palazzo, Gianfranco Filippelli, Bruno Vincenzi, Enrico Barbato, Gregorio Cennamo, Ferdinando Riccardi, Gabriella Misso, Michele Caraglia & Raffaele Addeo. (2014) Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey. Future Oncology 10:1, pages 69-78.
Crossref
Crossref
Jakob Mørkeberg. (2013) Blood manipulation: current challenges from an anti-doping perspective. Hematology 2013:1, pages 627-631.
Crossref
Crossref
Monika Farys, Claire L. Ginn, George O. Badescu, Karolina Peciak, Estera M. Pawlisz, Hanieh Khalili & Steve J. Brocchini. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
52
.
Bita Mesgarpour, Benedikt H. Heidinger, Michael Schwameis, Calvin Kienbacher, Cathal Walsh, Susanne Schmitz & Harald Herkner. (2013) Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis. Intensive Care Medicine 39:11, pages 1896-1908.
Crossref
Crossref
Tilman B. Dr?eke. (2013) Anemia Treatment in Patients with Chronic Kidney Disease. New England Journal of Medicine 368:4, pages 387-389.
Crossref
Crossref
Wolfgang Jelkmann. 2013. Introduction to Biological and Small Molecule Drug Research and Development. Introduction to Biological and Small Molecule Drug Research and Development
307
326
.